Education
About Us
Working with TipRanks
Follow Us
Estrella Immunopharma (ESLA)
NASDAQ:ESLA
RESEARCH TOOLSreports
ESLA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.63 - $3.23
Previous Close$1.15
Volume4.72K
Average Volume (3M)108.53K
Market Cap
$33.63M
Enterprise ValueN/A
Total Cash (Recent Filing)$9.05M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.54
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding36,165,590
10 Day Avg. Volume35,498
30 Day Avg. Volume108,525
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)730.82
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$16.00Price Target Upside1532.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Estrella Immunopharma News
PremiumCompany Announcements
Estrella Immunopharma Appoints Dr. Cheng Liu as CEOPremiumCompany Announcements
Estrella Immunopharma Welcomes New Chairperson, Expands BoardPremiumCompany Announcements
Estrella Immunopharma Unveils Updated Investor Presentation---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.30% Mutual Funds
0.14% Other Institutional Investors
99.44% Public Companies and
Individual Investors
ESLA FAQ
What was Estrella Immunopharma’s price range in the past 12 months?
Estrella Immunopharma lowest stock price was $0.63 and its highest was $3.23 in the past 12 months.
What is Estrella Immunopharma’s market cap?
Estrella Immunopharma’s market cap is $33.63M.
When is Estrella Immunopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Estrella Immunopharma’s earnings last quarter?
Currently, no data Available
Is Estrella Immunopharma overvalued?
According to Wall Street analysts Estrella Immunopharma’s price is currently Undervalued.
Does Estrella Immunopharma pay dividends?
Estrella Immunopharma does not currently pay dividends.
What is Estrella Immunopharma’s EPS estimate?
Estrella Immunopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Estrella Immunopharma have?
Estrella Immunopharma has 36,165,590 shares outstanding.
What happened to Estrella Immunopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Estrella Immunopharma?
Currently, no hedge funds are holding shares in ESLA
---
Estrella Immunopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (1532.65% Upside)
$16.00 (1532.65% Upside)
Blogger Sentiment
Bullish
ESLA Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 255.0K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.60%
12-Months-Change
Fundamentals
Return on Equity
-192.50%
Trailing 12-Months
Asset Growth
-66.75%
Trailing 12-Months
Company Description
Estrella Immunopharma
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
---
ESLA Stock 12 Month Forecast
Average Price Target
$16.00
▲(1532.65% Upside)
Technical Analysis
Agenus
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Blueprint Medicines
―
Adaptimmune Therapeutics
―
Best Analysts Covering ESLA
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-31.90%
initiated a buy rating last month
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -31.90% per trade.
---